-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Innate Pharma, Maintains $9 Price Target

Benzinga·09/17/2026 15:51:41
Listen to the news
BTIG analyst Jeet Mukherjee reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $9 price target.